{"description":"Documents published on or after 10/10/2026 and from Drug Enforcement Administration","count":38,"total_pages":2,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bagencies%5D%5B%5D=drug-enforcement-administration&conditions%5Bpublication_date%5D%5Bgte%5D=2026-10-10&format=json&page=2&search_after_cursor=WzE3OTI5NzI4MDAwMDAsIjIwMjYtMjE3MjUiXQ","results":[{"title":"Dave Allen Wright, M.D.; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-23508","html_url":"https://www.federalregister.gov/documents/2026/11/19/2026-23508/dave-allen-wright-md-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-19/pdf/2026-23508.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-23508.pdf?1795009508","publication_date":"2026-11-19","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":null},{"title":"Kyndahl D. Bertram, D.O.; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-23513","html_url":"https://www.federalregister.gov/documents/2026/11/18/2026-23513/kyndahl-d-bertram-do-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-18/pdf/2026-23513.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-23513.pdf?1794923134","publication_date":"2026-11-18","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":null},{"title":"Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV","type":"Rule","abstract":"On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place oveporexton, chemically known as N-[(2S,3R)-2-[[3-(3,5- difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2- methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide, in schedule IV of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing oveporexton, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule IV of the CSA.","document_number":"2026-23075","html_url":"https://www.federalregister.gov/documents/2026/11/12/2026-23075/schedules-of-controlled-substances-placement-of-oveporexton-in-schedule-iv","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-12/pdf/2026-23075.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-23075.pdf?1794258909","publication_date":"2026-11-12","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug..."},{"title":"Importer of Controlled Substances Application: NSI Lab Solutions LLC","type":"Notice","abstract":"NSI Lab Solutions LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.","document_number":"2026-23006","html_url":"https://www.federalregister.gov/documents/2026/11/12/2026-23006/importer-of-controlled-substances-application-nsi-lab-solutions-llc","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-12/pdf/2026-23006.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-23006.pdf?1794318321","publication_date":"2026-11-12","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"NSI Lab Solutions LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information."},{"title":"Troy R. Lehman, D.O.; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-22955","html_url":"https://www.federalregister.gov/documents/2026/11/12/2026-22955/troy-r-lehman-do-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-12/pdf/2026-22955.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22955.pdf?1794318315","publication_date":"2026-11-12","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":null},{"title":"Traci B. Lujan, A.P.R.N.; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-22954","html_url":"https://www.federalregister.gov/documents/2026/11/12/2026-22954/traci-b-lujan-aprn-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-12/pdf/2026-22954.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22954.pdf?1794318315","publication_date":"2026-11-12","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":null},{"title":"Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027","type":"Notice","abstract":"The Drug Enforcement Administration (DEA) proposes to establish the 2027 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.","document_number":"2026-22843","html_url":"https://www.federalregister.gov/documents/2026/11/10/2026-22843/proposed-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment-of","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-10/pdf/2026-22843.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22843.pdf?1794231909","publication_date":"2026-11-10","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"The Drug Enforcement Administration (DEA) proposes to establish the 2027 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals..."},{"title":"Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)","type":"Notice","abstract":"The Drug Enforcement Administration (DEA) is adjusting the 2026 aggregate production quota for the schedule II controlled substances d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). In making this determination, DEA has considered the factors set forth in 21 CFR 1303.13(b) in accordance with 21 U.S.C. 826(a) and is expediting publication of this determination to comply with the timeframes specified in 21 U.S.C. 826(h)(1).","document_number":"2026-22842","html_url":"https://www.federalregister.gov/documents/2026/11/10/2026-22842/adjustment-to-the-2026-aggregate-production-quota-for-dl-amphetamine-d-amphetamine-for-sale","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-10/pdf/2026-22842.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22842.pdf?1794231908","publication_date":"2026-11-10","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"The Drug Enforcement Administration (DEA) is adjusting the 2026 aggregate production quota for the schedule II controlled substances d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). In making this determination,..."},{"title":"Specific Listing for 3-Chloromethcathinone, A Currently Controlled Schedule I Substance","type":"Rule","abstract":"The Drug Enforcement Administration (DEA) is establishing a specific listing and DEA Controlled Substances Code Number (drug code) for 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3- chloromethcathinone; 3-CMC) in schedule I of the Controlled Substances Act (CSA). Although 3-chloromethcathinone is not specifically listed in schedule I of the CSA with its own unique drug code, it is a schedule I controlled substances in the United States because it is a positional isomer of 4-chloromethcathinone, which is a schedule I hallucinogen. Therefore, DEA is simply amending the schedule I hallucinogenic substances list in its regulations to separately include 3- chloromethcathinone.","document_number":"2026-22717","html_url":"https://www.federalregister.gov/documents/2026/11/06/2026-22717/specific-listing-for-3-chloromethcathinone-a-currently-controlled-schedule-i-substance","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-06/pdf/2026-22717.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22717.pdf?1793886316","publication_date":"2026-11-06","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"The Drug Enforcement Administration (DEA) is establishing a specific listing and DEA Controlled Substances Code Number (drug code) for 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3- chloromethcathinone; 3-CMC) in schedule I of the Controlled..."},{"title":"Bulk Manufacturer of Controlled Substances Application: Navinta LLC","type":"Notice","abstract":"Navinta LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.","document_number":"2026-22556","html_url":"https://www.federalregister.gov/documents/2026/11/05/2026-22556/bulk-manufacturer-of-controlled-substances-application-navinta-llc","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-05/pdf/2026-22556.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22556.pdf?1793799912","publication_date":"2026-11-05","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Navinta LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information."},{"title":"Importer of Controlled Substances Application: Diamond Animal Health, Inc.","type":"Notice","abstract":"Diamond Animal Health, Inc., has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.","document_number":"2026-22555","html_url":"https://www.federalregister.gov/documents/2026/11/05/2026-22555/importer-of-controlled-substances-application-diamond-animal-health-inc","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-05/pdf/2026-22555.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22555.pdf?1793799912","publication_date":"2026-11-05","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Diamond Animal Health, Inc., has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information."},{"title":"Importer of Controlled Substances Application: Noramco","type":"Notice","abstract":"Noramco has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.","document_number":"2026-22553","html_url":"https://www.federalregister.gov/documents/2026/11/05/2026-22553/importer-of-controlled-substances-application-noramco","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-05/pdf/2026-22553.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22553.pdf?1793799912","publication_date":"2026-11-05","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Noramco has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information."},{"title":"Technical Amendment to the Regulation Regarding Amendments to Applications","type":"Rule","abstract":"This final rule updates a Drug Enforcement Administration regulation to clarify that the provision regarding amendments to and withdrawal of registration applications also applies to applications for registration renewal. This action makes no substantive changes to this regulation.","document_number":"2026-22484","html_url":"https://www.federalregister.gov/documents/2026/11/04/2026-22484/technical-amendment-to-the-regulation-regarding-amendments-to-applications","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-04/pdf/2026-22484.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22484.pdf?1793713511","publication_date":"2026-11-04","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"This final rule updates a Drug Enforcement Administration regulation to clarify that the provision regarding amendments to and withdrawal of registration applications also applies to applications for registration renewal. This action makes no..."},{"title":"Bulk Manufacturer of Controlled Substances Application: AJNA Biosciences","type":"Notice","abstract":"AJNA Biosciences has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.","document_number":"2026-22289","html_url":"https://www.federalregister.gov/documents/2026/11/02/2026-22289/bulk-manufacturer-of-controlled-substances-application-ajna-biosciences","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-02/pdf/2026-22289.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22289.pdf?1793364312","publication_date":"2026-11-02","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"AJNA Biosciences has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information."},{"title":"Importer of Controlled Substances Application: Globyz Pharma LLC","type":"Notice","abstract":"Globyz Pharma LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.","document_number":"2026-22288","html_url":"https://www.federalregister.gov/documents/2026/11/02/2026-22288/importer-of-controlled-substances-application-globyz-pharma-llc","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-02/pdf/2026-22288.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22288.pdf?1793364312","publication_date":"2026-11-02","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Globyz Pharma LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information."},{"title":"Conforming Amendment Regarding the Criminal Law Technical Amendments Act of 2002","type":"Rule","abstract":"The Criminal Law Technical Amendments Act of 2002 (\"Technical Amendments Act\") became law on November 2, 2002, as part of the 21st Century Department of Justice Appropriations Authorization Act. The Technical Amendments Act amended sections 401(d), 402(c), and 403 of the Controlled Substances Act by replacing outmoded fine amounts with a reference to title 18 of the United States Code in each place that a specific fine amount had appeared. In this rulemaking, the Drug Enforcement Administration (DEA) is amending its regulations to conform them to the statutory amendments made to the Controlled Substances Act by the Technical Amendments Act.","document_number":"2026-22285","html_url":"https://www.federalregister.gov/documents/2026/11/02/2026-22285/conforming-amendment-regarding-the-criminal-law-technical-amendments-act-of-2002","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-02/pdf/2026-22285.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22285.pdf?1793364311","publication_date":"2026-11-02","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"The Criminal Law Technical Amendments Act of 2002 (\"Technical Amendments Act\") became law on November 2, 2002, as part of the 21st Century Department of Justice Appropriations Authorization Act. The Technical Amendments Act amended sections 401(d),..."},{"title":"Schedules of Controlled Substances: Placement of Centanafadine in Schedule III","type":"Rule","abstract":"On July 24, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder in adults and pediatric patients aged 6 years and older, weighing at least 20 kg. The Department of Health and Human Services provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place centanafadine, chemically known as (1R,5S)-1- (naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in schedule III of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing centanafadine, including its salts, isomers (whether optical, positional, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible in schedule III of the CSA.","document_number":"2026-22208","html_url":"https://www.federalregister.gov/documents/2026/10/30/2026-22208/schedules-of-controlled-substances-placement-of-centanafadine-in-schedule-iii","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-30/pdf/2026-22208.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22208.pdf?1793277918","publication_date":"2026-10-30","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"On July 24, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder in adults and pediatric patients aged 6 years and older,..."},{"title":"Bulk Manufacturer of Controlled Substances Application: Sigma Aldrich Research Biochemicals, Inc.","type":"Notice","abstract":"Sigma Aldrich Research Biochemicals, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.","document_number":"2026-22048","html_url":"https://www.federalregister.gov/documents/2026/10/29/2026-22048/bulk-manufacturer-of-controlled-substances-application-sigma-aldrich-research-biochemicals-inc","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-29/pdf/2026-22048.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-22048.pdf?1793191513","publication_date":"2026-10-29","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"Sigma Aldrich Research Biochemicals, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information."},{"title":"Vida Janson, M.D.; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-21799","html_url":"https://www.federalregister.gov/documents/2026/10/26/2026-21799/vida-janson-md-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-26/pdf/2026-21799.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-21799.pdf?1792759518","publication_date":"2026-10-26","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":null},{"title":"Barry Backiewicz, D.D.S.; Decision and Order","type":"Notice","abstract":null,"document_number":"2026-21725","html_url":"https://www.federalregister.gov/documents/2026/10/26/2026-21725/barry-backiewicz-dds-decision-and-order","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-10-26/pdf/2026-21725.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-21725.pdf?1792759510","publication_date":"2026-10-26","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":null}]}